Related Experiment Video

Updated: Nov 7, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

436

Next Generation Therapeutics for the Treatment of Myelofibrosis

Douglas Tremblay1, John Mascarenhas1

  • 1Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA.

Cells
|April 30, 2021
PubMed

Insights

Novel therapies targeting myelofibrosis beyond JAK inhibitors are emerging. These agents address apoptosis, epigenetics, and the bone marrow microenvironment, offering new hope for patients with this myeloproliferative neoplasm.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myelofibrosis is a myeloproliferative neoplasm with significant morbidity.
  • Current JAK inhibitor therapy improves symptoms but not disease progression.
  • Many patients are ineligible for or refractory to JAK inhibitors, necessitating new treatments.

Purpose of the Study:

  • To review novel, non-JAK inhibitor-based therapies under investigation for myelofibrosis.
  • To discuss agents targeting apoptosis, epigenetic modulation, bone marrow microenvironment, and other pathways.
  • To provide an overview of preclinical and clinical data for emerging myelofibrosis treatments.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Focus on agents targeting pathways distinct from JAK-STAT.
  • Analysis of mechanisms, rationale, efficacy, and safety of novel agents.

Main Results:

  • Several novel agents targeting apoptosis (e.g., navitoclax), epigenetic modulation (e.g., CPI-0610), and the bone marrow microenvironment (e.g., PRM-151) show promise.
  • These agents are in various stages of clinical development.
  • Early data suggest potential for improved outcomes in myelofibrosis patients.

Conclusions:

  • Non-JAK inhibitor therapies represent a promising frontier in myelofibrosis treatment.
  • Targeting diverse pathways offers potential for improved disease control and patient survival.
  • Further clinical investigation is crucial to establish the role of these novel agents.
Keywords:
Aurora kinaseBCL-2/xLBETCD123LSD1MDM2PI3KPRM-151TGFbmyelofibrosistelomerase

More Related Videos

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
271
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.4K